Symfony/Synergy IOL Combination Outcomes

Inclusion Criteria:

1. Subject is undergoing bilateral lens extraction with intraocular lens implantation ofthe Symfony with InteliLight in the dominant eye and a Synergy in the non-dominanteye.
2. Gender: Males and Females.
3. Age: 50 years and older.
4. Willing and able to provide written informed consent for participation in the study
5. Willing and able to comply with scheduled visits and other study procedures.
6. Scheduled to undergo standard cataract surgery with topical anesthesia in both eyeswithin 2 to 30 days between surgeries
7. Subjects who require an IOL power in the range of +5.00 D to +34.0 D only.
8. Subjects who require a toric IOL up to +3.75 D at the IOL plane (2.57 D cornealplane).
9. Potential postoperative visual acuity of 0.2 logMAR (20/32 Snellen) or better in botheyes.

Exclusion Criteria:

1. Severe preoperative ocular pathology: amblyopia, rubella cataract, proliferativediabetic retinopathy, shallow anterior chamber, macular edema, retinal detachment,aniridia or iris atrophy, uveitis, history of iritis, iris neovascularization,medically uncontrolled glaucoma, microphthalmos or macrophthalmos, optic nerveatrophy, macular degeneration (with anticipated best postoperative visual acuity lessthan 20/30), advanced glaucomatous damage, etc.
2. Uncontrolled diabetes.
3. Use of any systemic or topical drug known to interfere with visual performance.
4. Contact lens use during the active treatment portion of the trial.
5. Any concurrent infectious/non-infectious conjunctivitis, keratitis or uveitis.
6. Clinically significant corneal dystrophy
7. History of chronic intraocular inflammation.
8. History of retinal detachment.
9. Pseudoexfoliation syndrome or any other condition that has the potential to weaken thezonules.
10. Previous intraocular surgery.
11. Previous corneal refractive surgery (i.e. LASIK, photorefractive keratectomy, radialkeratotomy).
12. Previous keratoplasty
13. Severe dry eye
14. Pupil abnormalities
15. Anesthesia other than topical or peribulbar anesthesia (i.e. retrobulbar, general,etc).
16. Any clinically significant, serious or severe medical or psychiatric condition thatmay increase the risk associated with study participation or may interfere with theinterpretation of study results.
17. Participation in (or current participation) any ophthalmic investigational drug orophthalmic device trial within the previous 30 days prior to the start date of thistrial.